NGLY1 deficiency is the first recognized autosomal recessive disorder of N-linked deglycosylation (NGLY1-CDDG). This severe multisystemic disease is still poorly known and, to date, most cases have been diagnosed through whole exome or genome sequencing. The aim of this study is to provide the clinical, biochemical and molecular description of the first NGLY1-CDDG patient from France along with a literature review. The index case presented with developmental delay, acquired microcephaly, hypotonia, alacrimia, feeding difficulty, and dysmorphic features. Given the complex clinical picture and the multisystemic involvement, a trio-based exome sequencing was conducted and urine oligosaccharides were assessed using mass spectrometry. The exome sequencing revealed a novel variant in the NGLY1 gene in a homozygous state. NGLY1 deficiency was confirmed by the identification of the Neu5Ac1Hex1GlcNAc1-Asn oligosaccharide in the urine of the patient. Literature review revealed the association of some key clinical and biological features such as global developmental delay—hypertransaminasemia, movement disorders, feeding difficulties and alacrima/hypolacrima.
(1) Background: Glioblastoma is the most common malignant brain tumor in adults. Its etiology remains unknown in most cases. Glioblastoma pathogenesis consists of a progressive infiltration of the white matter by tumoral cells leading to progressive neurological deficit, epilepsy, and/or intracranial hypertension. The mean survival is between 15 to 17 months. Given this aggressive prognosis, there is an urgent need for a better understanding of the underlying mechanisms of glioblastoma to unveil new diagnostic strategies and therapeutic targets through a deeper understanding of its biology. (2) Methods: To systematically address this issue, we performed targeted and untargeted metabolomics-based investigations on both tissue and plasma samples from patients with glioblastoma. (3) Results: This study revealed 176 differentially expressed lipids and metabolites, 148 in plasma and 28 in tissue samples. Main biochemical classes include phospholipids, acylcarnitines, sphingomyelins, and triacylglycerols. Functional analyses revealed deep metabolic remodeling in glioblastoma lipids and energy substrates, which unveils the major role of lipids in tumor progression by modulating its own environment. (4) Conclusions: Overall, our study demonstrates in situ and systemic metabolic rewiring in glioblastoma that could shed light on its underlying biological plasticity and progression to inform diagnosis and/or therapeutic strategies.
Background: Fabry disease (FD) is an X-linked lysosomal disease due to a deficiency in the activity of the lysosomal α-galactosidase A (GalA), a key enzyme in the glycosphingolipid degradation pathway. FD is a complex disease with a poor genotype–phenotype correlation. FD could involve kidney, heart or central nervous system impairment that significantly decreases life expectancy. The advent of omics technologies offers the possibility of a global, integrated and systemic approach well-suited for the exploration of this complex disease. Materials and Methods: Sixty-six plasmas of FD patients from the French Fabry cohort (FFABRY) and 60 control plasmas were analyzed using liquid chromatography and mass spectrometry-based targeted metabolomics (188 metabolites) along with the determination of LysoGb3 concentration and GalA enzymatic activity. Conventional univariate analyses as well as systems biology and machine learning methods were used. Results: The analysis allowed for the identification of discriminating metabolic profiles that unambiguously separate FD patients from control subjects. The analysis identified 86 metabolites that are differentially expressed, including 62 Glycerophospholipids, 8 Acylcarnitines, 6 Sphingomyelins, 5 Aminoacids and 5 Biogenic Amines. Thirteen consensus metabolites were identified through network-based analysis, including 1 biogenic amine, 2 lysophosphatidylcholines and 10 glycerophospholipids. A predictive model using these metabolites showed an AUC-ROC of 0.992 (CI: 0.965–1.000). Conclusion: These results highlight deep metabolic remodeling in FD and confirm the potential of omics-based approaches in lysosomal diseases to reveal clinical and biological associations to generate pathophysiological hypotheses.
3 February 2022 in Molecular Genetics and Metabolism
Schizophrenia (SCZ) is one of the most severe mental disorders. Several elements involved in pathogenesis have been characterized recently. However, tools for diagnosis and risk prediction are limited. Elucidation of the underlying genomic and molecular mechanisms of SCA remains a challenge. In this study, we aimed to identify plasma biomarkers for SCZ using targeted metabolomics. All enrolled patients were drug-free for at least 3 months prior to admission. Plasma from 31 SCZ patients and 70 matched controls were analyzed using the LC/MS- Api 4000 QTrap Sciex. A total of 188 targeted metabolites, including 21 amino acids, 21 biogenic amines and 145 lipids or lipid-related metabolites were analyzed. All data modeling and analysis is done using MetaboAnalyst 5.0 There was no significant difference in the studied groups regarding BMI. Plasma Triglycerides, LDL-C, total proteins levels were significantly decreased in SCZ compared to controls. Heatmap identified 2 clusters with 25 significantly differentially expressed metabolites (FDR <0.05) between the drug-naïve group and the matched controls. The OPLS-DA score plot showed that the groups are clearly separated according to plasma phospholipids concentrations. Among these differential metabolites, the expression level of very long chain Phosphatidylcholines (PC 36 – PC p42) and acylcarnitines were significantly decreased in SCZ compared to controls, whereas sphingomyelin (SM) and lysoPC were significantly lower in drug-naive patients. In this study, we found that plasma phospholipids were significantly dysregulated in the SCZ patients and could be a promising pathway to explore SCZ. None Declared
Les maladies héréditaires du métabolisme (MHM) sont des affections génétiques résultant d'anomalies au sein de voies biochimiques spécifiques. Elles sont dues à un déficit d’une enzyme, de son cofacteur ou d'un transporteur. La médecine des systèmes (MS) est un moteur moderne pour la recherche biomédicale intégrant des données multimodales pour mieux comprendre les réseaux biologiques et améliorer la stratification des patients. Grâce à des stratégies basées sur la valorisation des données biomédicales et l’expertise clinique, la MS promet d'améliorer la prévention, diagnostic et le traitement des MHM. Dans cette thèse, nous avons adopté des approches multiomique et phénomique combinées à des stratégies d'apprentissage automatique et d’analyse des réseaux pour caractériser deux maladies lysosomales, maladie de Fabry (MF) et maladie de Gaucher (MD). Le premier projet a porté sur la MF et a permis d'identifier des profils omiques plasmatiques (métabolites et protéines) discriminant des patients Fabry. De plus, nous avons observé un remodelage métabolique de plusieurs processus biologiques, tels que les voies médiées par les cytokines, la matrice extracellulaire et le protéome vacuolaire/lysosomal. Nos découvertes mettent en évidence l'implication des cytokines pro-inflammatoires dans la pathogenèse de la MF, ainsi que la réorganisation de la matrice extracellulaire. Le deuxième projet a porté sur la MG de type 1. Les résultats ont révélé des empreintes biologiques plasmatiques. L'étude a révélé une perturbation significative du métabolisme des lipides, de l'inflammation et de la fonction mitochondriale, potentiellement attribuable au stress du réticulum endoplasmique, à un trafic lipidique altéré et à l'inhibition de l'autophagie. Dans le cadre de la thèse, nous avons évalué les performances analytiques d’un nouveau dispositif volumétrique de collecte de sang par micro-échantillonnage comparativement au sang séché sur buvard pour le dosage de l’activité des enzymes lysosomales. Par ailleurs, une méthode à haut débit a été développée pour évaluer les lysosphingolipides (biomarqueurs pour les sphingolipidoses). En résumé, une approche intégrative multiomique et phénomique a été utilisée pour étudier deux sphingolipidoses, révélant des empreintes plasmatiques biologiques spécifiques.